Clopidogrel Tablet, Film Coated
Product Images NDC 70518-1898

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 70518-1898). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Clopidogrel 75 mg film-coated tablets, quantity 30 tablets. The label indicates it is for prescription use only (RX ONLY) with NDC 70518-1898-01. Manufactured by Aurobindo, India, and repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions specify 20-25°C with permitted excursions. The label features a barcode and a QR code, along with the RemedyRepack logo.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of Clopidogrel Bisulfate 75 mg. The graph compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with each bar including mean values and 90% confidence intervals. The x-axis measures change relative to Clopidogrel bisulfate administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A cumulative event rate line chart comparing cardiovascular death, myocardial infarction, and stroke rates over 12 months of follow-up between patients treated with placebo plus aspirin and those treated with clopidogrel bisulfate plus aspirin. The graph shows a consistently lower event rate for the clopidogrel bisulfate group versus placebo, with a statistically significant p-value of 0.00009.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A data table displaying subgroup hazard ratio analysis comparing Clopidogrel Bisulfate versus placebo across various demographic and clinical subgroups, including age, gender, race, diabetes status, previous medical conditions, and concurrent medications. The table lists the number of subjects, event counts, percentages, and contains a forest plot visualizing hazard ratios with confidence intervals for each subgroup and overall outcomes.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier curve chart showing the percentage of deaths before first discharge over time (days since randomization up to 28 days) for patients taking Clopidogrel versus placebo. The chart compares survival, with lines indicating death percentages for placebo (8.1%) and Clopidogrel (7.5%), noting a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A cumulative event plot comparing the percentage of patients experiencing death, re-infarction, or stroke over 28 days since randomization between Clopidogrel and placebo groups. The graph shows event percentages increasing over time, with Clopidogrel group events lower (9.2%) than placebo (10.1%), indicating a 9% proportional risk reduction (p=0.002).*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart presenting odds ratios and 99% confidence intervals comparing Clopidogrel Bisulfate to placebo across patient subgroups defined by gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart visually indicates the effect favors either Clopidogrel Bisulfate or placebo for each subgroup and overall population in the clinical study.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph titled 'FATAL OR NON-FATAL VASCULAR EVENTS' comparing cumulative event rate (%) over months of follow-up between Aspirin and Clopidogrel Bisulfate. The x-axis shows months of follow-up from 0 to 36, and the y-axis shows cumulative event rate percentage from 0 to 16%. Two lines represent Aspirin and Clopidogrel Bisulfate, with Aspirin showing slightly higher cumulative event rates. A p-value of 0.045 is indicated on the chart.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A hazard ratio plot showing the comparisons of Clopidogrel Bisulfate versus Aspirin outcomes for qualifying conditions: Stroke, MI (Myocardial Infarction), PAD (Peripheral Artery Disease), and Overall. The horizontal axis represents the hazard ratio with 95% confidence intervals ranging from 0.6 to 1.3, indicating favorability toward Clopidogrel Bisulfate or Aspirin for each condition based on event frequencies.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate, showing its molecular arrangement including a thiophene ring, ester group, chlorine-substituted phenyl ring, and sulfate component. This structure represents the active ingredient in Clopidogrel 75 mg film-coated tablets by RemedyRepack Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.